J&J Consumer Business Picks Up, But Analysts See Long Road
This article was originally published in The Tan Sheet
Executive Summary
The consumer business inched up 1% operationally in Q3, including about 6% growth at constant currency in OTC/nutritionals. However, costs associated with the remediation of McNeil OTC facilities are expected to weigh on J&J through most of 2013.
You may also be interested in...
China FDA Highlights Product Recalls, Manufacturers Urged To Make Rapid Responses
Despite being one of the largest medical product markets in the world, China has seen few product recalls. The situation could be changing however as China FDA has requested drug and device manufacturers to quickly withdraw products that have deficiencies and potential safety risks.
China FDA Highlights Product Recalls, Manufacturers Urged To Make Rapid Responses
Despite being one of the largest medical product markets in the world, China has seen few product recalls. The situation could be changing however as China FDA has requested drug and device manufacturers to quickly withdraw products that have deficiencies and potential safety risks.
Bapineuzumab Failure Raises More Doubts About Beta Amyloid Approach In Alzheimer’s
As many observers expected, top-line results from a Phase III study show bapineuzumab doesn’t work in carriers of the ApoE4 gene, who are at highest risk for Alzheimer’s disease. An interim analysis of another Phase III study in carriers will now be “expedited,” and other studies of non-carriers will keep going, Pfizer says.